quinoxalines has been researched along with Endometrial Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Backes, F; Birrer, M; Campana, F; Egile, C; Ghamande, S; Martin, LP; Matulonis, U; McMeekin, S; Vergote, I; Xu, Y | 1 |
| Arimoto, T; Fujii, T; Fukuda, T; Ikeda, Y; Inaba, K; Kashiyama, T; Kawana, K; Kuramoto, H; Miyasaka, A; Oda, K; Osuga, Y; Sone, K; Uehara, Y; Wada-Hiraike, O; Yano, T | 1 |
1 trial(s) available for quinoxalines and Endometrial Neoplasms
| Article | Year |
|---|---|
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides | 2015 |
1 other study(ies) available for quinoxalines and Endometrial Neoplasms
| Article | Year |
|---|---|
Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases | 2015 |